380 related articles for article (PubMed ID: 20848767)
21. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
22. Oncology drug lag in Japan: has it improved over the last decade?
Tachibana Y; Narukawa M
Int J Clin Oncol; 2023 Nov; 28(11):1451-1460. PubMed ID: 37561368
[TBL] [Abstract][Full Text] [Related]
23. Decision and timing of safety-related labeling changes for new drugs in Japan: Comparison with the United States and the European Union.
Fukuda K; Narukawa M
Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1331-1340. PubMed ID: 37395168
[TBL] [Abstract][Full Text] [Related]
24. Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study.
Hwang TJ; Sokolov E; Franklin JM; Kesselheim AS
BMJ; 2016 Jun; 353():i3323. PubMed ID: 27352914
[TBL] [Abstract][Full Text] [Related]
25. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
Maeda H; Kurokawa T
Int J Clin Oncol; 2015 Dec; 20(6):1072-80. PubMed ID: 25837976
[TBL] [Abstract][Full Text] [Related]
26. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
27. Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.
Maki A; Narukawa M
Ther Innov Regul Sci; 2023 Jul; 57(4):671-677. PubMed ID: 36966205
[TBL] [Abstract][Full Text] [Related]
28. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.
Maeda H; Kurokawa T
J Clin Pharmacol; 2015 May; 55(5):481-9. PubMed ID: 25560978
[TBL] [Abstract][Full Text] [Related]
29. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
Hartmann M; Mayer-Nicolai C; Pfaff O
Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
[TBL] [Abstract][Full Text] [Related]
30. Different Development Strategies Affecting Japan's Drug lag between Japan-Based and Foreign-Based Companies.
Hidaka M; Hanaoka H; Uyama Y
Ther Innov Regul Sci; 2024 Jul; 58(4):714-720. PubMed ID: 38575785
[TBL] [Abstract][Full Text] [Related]
31. Research and development of mAb drugs in China: a look from policy perspectives.
Jiang R; Sun Y; Ung C; Dong X; Kong X; Hu Y; Shao R
Hum Vaccin Immunother; 2019; 15(11):2695-2705. PubMed ID: 31116629
[No Abstract] [Full Text] [Related]
32. [Delays in clinical development of neurological drugs in Japan].
Ikeda M
Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
Jokura Y; Yano K; Yamato M
J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
[TBL] [Abstract][Full Text] [Related]
34. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
Nagai S; Ozawa K
Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
[TBL] [Abstract][Full Text] [Related]
35. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
Rawson NS
J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
[TBL] [Abstract][Full Text] [Related]
36. Delays in neurological drug development in Japan.
Shimazawa R; Ikeda M
Intern Med; 2011; 50(15):1565-8. PubMed ID: 21804282
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
Vokinger KN; Kesselheim AS; Glaus CEG; Hwang TJ
JAMA Health Forum; 2022 Aug; 3(8):e222685. PubMed ID: 36200635
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021.
Luo X; Du X; Li Z; Qian F; Yang Y
Clin Pharmacol Ther; 2023 Jan; 113(1):170-181. PubMed ID: 36151921
[TBL] [Abstract][Full Text] [Related]
39. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan.
Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
Br J Clin Pharmacol; 2021 Aug; 87(8):3279-3291. PubMed ID: 33511674
[TBL] [Abstract][Full Text] [Related]
40. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.
Heemstra HE; Giezen TJ; Mantel-Teeuwisse AK; de Vrueh RL; Leufkens HG
Drug Saf; 2010 Feb; 33(2):127-37. PubMed ID: 20082539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]